Health Highlights: July 19, 2011

By on July 19, 2011

Here are some of the latest health and medical news developments, compiled by the editors of HealthDay:

12 States Have Obesity Rates of at Least 30%: CDC

A dozen U.S. states now have obesity rates of 30 percent or higher, up from nine states three years ago. No states met the threshold in 2000, the U.S. Centers for Disease Control and Prevention said Tuesday.

Obesity is now a problem in all 50 states, the agency said in a news release. An adult is considered obese if he or she has a body mass index (BMI) of 30 or greater.

No state met the federal Healthy People 2010 goal of a 15 percent obesity rate. In fact, no state had a rate lower than 20 percent, the CDC said.

The agency interviewed by telephone some 400,000 adults nationwide. Regionally, the South had the highest obesity rate at 29.4 percent; the Midwest, 28.7 percent; the Northeast, 24.9 percent and the West 24.1, percent.

Some of the top causes of death are linked to obesity, including heart disease, stroke, type 2 diabetes, and certain cancers, the CDC said.


Users of Antipsychotic Warned of Possible Drug Interactions

The maker of the popular antipsychotic drug Seroquel will add a warning to its label saying that if it is taken with any of at least 12 other drugs, the interaction could lead to an irregular heartbeat and possible heart attack, The New York Times reported.

A spokeswoman for the U.S. Food and Drug Administration clarified that the label warning to be posted by drug maker AstraZeneca was intended as a precaution for doctors, whom she said could still prescribe Seroquel and one of the other drugs if necessary.

FDA spokeswoman Sandy Walsh told the newspaper that the agency had notice of 17 cases of a certain type of heart arrhythmia among people who took above-recommended amounts of Seroquel and at least one other medication.

The heart rhythm abnormality, called prolongation of the QT interval, is responsible for several thousand deaths in the United States each year, the Times reported.

Drugs that shouldn’t be taken in tandem with Seroquel include antiarrhythmic drugs such as quinidine, procainamide, amiodarone and sotalel; antispsychotics such as ziprasidone, chlorpromazine and thioridazine; antibiotics such as gatifloxacin and moxifloxacin; the anti-infective drug pentamidine; and synthetic opioids such as levomethadyl acetate and methadone, the Times reported.

Seroquel’s prior labeling had warned of heart arrhythmia risk but hadn’t mentioned other drugs that could interact with the antipsychotic, an AstraZeneca spokeswoman said.


Thinner Wife, Heavier Hubby Makes for Better Marriage: Study

Marriages tend to work better when a man is heftier than his wife, according to a new study of 169 newlyweds.

The study, published in the July issue of Social Psychological and Personality Science, tracked the couples over four years. Researchers found that when husbands had a higher body mass index than wives, husbands were more satisfied soon after vows were exchanged and wives were more satisfied over the long term, than if the situation was reversed.

“There’s a lot of pressure on women in our society to achieve an often unreachably small weight,” study lead author Andrea Meltzer, a doctoral candidate at the University of Tennessee, told ABC News. “The great take-home message from our study is that women of any size can be happy in their relationships with the right partner. It’s relative weight that matters, not absolute weight. It’s not that they have to be small.”

The finding remained strong even after the researchers accounted for stressors in a marriage, such as finances and depression.

Meltzer said it’s not clear how relative differences in weight affect marriage happiness, but “one idea is that attractiveness and weight are more important to men.”

But she stressed that weight is just one factor in marital bliss, and maintaining the relative weights noted in the study is “not a guarantee to be happy in a relationship.”


FDA Panel Mulling New Type of Diabetes Drug

A panel convened by the U.S. Food and Drug Administration will weigh this week the merits of the first of a new type of diabetes drug — but it’s far from certain that the drug, dapagliflozin, will reach the market.

According to The New York Times, the medicine helps diabetics reduce their blood sugar by excreting excess glucose via urine. But the FDA panelists are also poring over data suggesting that dapagliflozin raises users’ risks for genital and urinary tract infections, liver damage and breast and bladder cancer, the Times said.

The once-a-day pill — from an emerging class of medicines called SGLT2 inhibitors — is being developed by Bristol-Myers Squibb and AstraZeneca, but other companies have similar diabetes medications in the pipeline. In clinical trials, dapagliflozin appeared to be equally effective as other medications targeted to cut blood sugar levels. The FDA noted, however, that the drug is not effective in people with moderate to severe kidney dysfunction.

One advantage of SGLT2 inhibitors is that they work independently of insulin, so doctors might be more free to combine them with other medications. And the Times said that the elimination of glucose via urine might help users lose excess weight. In clinical trials, people taking dapagliflozin dropped an average of 5 pounds more than people who took a placebo after six months, and they also achieved a slight decrease in blood pressure.

Still, drawbacks were also observed. According to the Times, an increase of sugar in urine boosts the odds for urinary tract and genital infections, and there were slight hikes in cases of breast and bladder cancer in those patients on dapagliflozin.

Leave a Reply

Your email address will not be published. Required fields are marked *